PuSH - Publication Server of Helmholtz Zentrum München

Journal browsing

59 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Klann, K.* et al.: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia 36, 2396-2407 (2022)
2.
Mentz, M. et al.: PARP14 is a novel target in STAT6 mutant follicular lymphoma. Leukemia, DOI: 10.1038/s41375-022-01641-x (2022)
3.
Benmebarek, M.R.* et al.: A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia 35, 2243–2257 (2021)
4.
Stegelmann, F.* et al.: Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: Results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN (Leukemia, (2021), 35, 2, (628-631), 10.1038/s41375-020-0945-3). Leukemia, DOI: 10.1038/s41375-021-01366-3 (2021)
5.
Bamezai, S.* et al.: TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. Leukemia 35, 389–403 (2020)
6.
Bamopoulos, S.A.* et al.: Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia 34, 2621–2634 (2020)
7.
Herold, T. et al.: Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia 34, 3161–3172 (2020)
8.
Jensen, P.* et al.: Requirement for LIM kinases in acute myeloid leukemia. Leukemia 34, 3173–3185 (2020)
9.
Mason, M.J.* et al.: Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia 34, 1866–1874 (2020)
10.
Ruzicka, M.* et al.: RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. Leukemia 34, 1017-1026 (2020)
11.
Stegelmann, F.* et al.: Significant association of cutaneous adverse events with hydroxyurea: Results from a prospective non-interventional study inBCR-ABL1-negative myeloproliferative neoplasms (MPN)-on behalf of the German Study Group-MPN. Leukemia, DOI: 10.1038/s41375-020-0945-3 (2020)
12.
Stief, S.M.* et al.: Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia 34, 50-62 (2020)
13.
Tirado-Gonzalez, I.* et al.: Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC (Leukemia, (2018), 32, 4, (1048-1051), 10.1038/leu.2017.346). Leukemia 35:294 (2020)
14.
Angenendt, L.* et al.: The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia 33, 2830-2841 (2019)
15.
Lynch, J.R.* et al.: JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. Leukemia 33, 1400-1410 (2019)
16.
Vrzalikova, K.* et al.: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells (vol 32, pg 214, 2018). Leukemia 33, 2126-2126 (2019)
17.
Anastasiadou, E.* et al.: Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 33, 132–147 (2018)
18.
Reiter, K.* et al.: Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia 32, 313-322 (2018)
19.
Schneidt, V.* et al.: Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo. Leukemia 33, 88-98 (2018)
20.
Tirado-Gonzalez, I.* et al.: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 32, 1048-1051 (2018)